Infigratinib
 | |
| Clinical data | |
|---|---|
| Trade names | Truseltiq |
| Other names | BGJ-398 |
| License data |
|
| Pregnancy category | |
| Routes of administration | By mouth |
| Drug class | Tyrosine kinase inhibitor |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C26H31Cl2N7O3 |
| Molar mass | 560.48 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Infigratinib, sold under the brand name Truseltiq, is an anti-cancer medication used to treat cholangiocarcinoma (bile duct cancer).[1][4][5]
Infigratinib is a kinase inhibitor targeting the fibroblast growth factor receptors FGFR1, FGFR2 and FGFR3[6][4][5] It was designated an orphan drug by the U.S. Food and Drug Administration (FDA) in 2019,[7] and it was approved for medical use in the United States in May 2021.[5]
Medical uses
Infigratinib is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer) with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.[4]
References
- ^ a b c "Truseltiq". Therapeutic Goods Administration (TGA). 22 November 2021. Retrieved 28 December 2021.
- ^ "Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 12 May 2022. Retrieved 13 May 2022.
- ^ "Summary Basis of Decision (SBD) for Truseltiq". Health Canada. 23 October 2014. Retrieved 29 May 2022.
- ^ a b c d "Truseltiq- infigratinib capsule". DailyMed. Retrieved 10 June 2021.
- ^ a b c "BridgeBio Pharma's Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of Truseltiq (infigratinib) for Patients with Cholangiocarcinoma" (Press release). BridgeBio Pharma. 28 May 2021. Retrieved 28 May 2021 – via GlobeNewswire.
- ^ Botrus G, Raman P, Oliver T, Bekaii-Saab T (April 2021). "Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma". Expert Opinion on Investigational Drugs. 30 (4): 309–316. doi:10.1080/13543784.2021.1864320. PMID 33307867. S2CID 229177726.
- ^ "Infigratinib Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). 11 September 2019. Retrieved 30 May 2021.
External links
- "Infigratinib". Drug Information Portal. U.S. National Library of Medicine.
- Clinical trial number NCT02150967 for "A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma" at ClinicalTrials.gov
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |